Mário Osvaldo VrandecicI; Bayard Gontijo FilhoI; João Alfredo Paula e SilvaII; Fernando Antônio FantiniI; Juscelino Teixeira BarbosaII; Márcio C São José; Carlos Álvaro dos Santos PintoIII; Gilberto Lino VieiraIV; Homero Geraldo OliveiraIV; Renato R RabeloIV; Sebastião Correa RabelloIV; Alexandre V BrickV; Eduardo PeredoI; Adelson A PedrosaI; Antônio Luiz O Azevedo SobrinhoIII; Maurício BarbosaIII; Heberth César MiottoI; Maria Aparecida BragaIV; Marco Antônio SalumII; Júnia F BragaI; Guilherme H MoreiraI; Osvald Hely MoreiraI; Carlos Alberto de OliveiraIII; Flávio Justo MacielI
DOI: 10.1590/S0102-76381988000300002
RESUMO
No período de março de 1981 a março de 1988, foram implantadas 2324 biopróteses, em 2016 pacientes, em 5 Centros do Estado de Minas Gerais. Este estudo inclui somente a análise dos pacientes submetidos a troca valvar aórtica (n = 603) e mitral ( n = 1110), isoladamente. Neste grupo (n = 1713), a mortalidade hospitalar foi de 104 pacientes (6,1%). Dos 1609 pacientes que receberam alta do hospital, conseguimos o seguimento de 1101 pacientes (64,3). Esta análise corresponde a um período de 1 a 84 meses, com média de 48 meses e com um seguimento cumulativo de: aórticas (n= 385) = 1230 pacientes/ano; mitrais (n = 716) = 3018 pacientes/ano. Foram registradas 102 complicações tardias em 716 pacientes mitrais (14,24%) e 51 complicações no grupo aórtico (13,2%). Com relação à faixa etária, encontramos 220 pacientes menores de 20 anos (mitrais = 176/aórticos = 44) e, neste subgrupo, as disfunções valvares incidiram em 43% dos pacientes mitrais e em 29% dos pacientes aórticos. A endocardite protética foi mais encontrada nos aórticos (45%) do que nos mitrais (29,7%). Dos 1101 pacientes, 62 foram reoperados, com mortalidade hospitalar de 12,6%. A reoperação por disfunção valvar foi mais freqüente no grupo mitral com idade inferior a 20 anos. A curva atuarial livre de mortalidade relacionada à bioprótese foi de 97,1% (32/1101 pacientes). No grupo aórtico, 96,9% estiveram livres de disfunção valvar ao final de 7 anos, enquanto que, no grupo mitral, este índice foi de 95,2%. Nos pacientes menores de 20 anos do grupo mitral, encontramos o maior índice de falência valvar (85,3% livre após 7 anos). Ao final deste estudo, a maior parte destes pacientes encontrava-se em classe funcional I e II. Embora a incidência de reoperação seja expressiva, esta é aceitável, tendo em vista que as biopróteses oferecem uma alternativa mais segura do que as próteses mecânicas, durante este mesmo período do seguimento. A análise destes resultados sugere a continuação de pesquisas que tornem possível a fabricação de um substituto valvar ideal. Todavia, estes resultados comparam-se, de modo favorável, a resultados com biopróteses semelhantes da literatura mundial.ABSTRACT
From March 1981 to March 1988, 2324 bioprostheses were implanted in 2016 patients in 5 centers in the State of Minas Gerais. This study includes only the analysis of patients undergoing isolated aortic (n = 603) or mitral (n = 1110) valve replacement. The hospital mortality in this group (n = 1713) was 104 patients (6.1%). From the remaining 1609 patients, that were discharged from the hospital, we were able to obtain a follow-up in 1101 or 64.3%. This analysis related to a period ranging from 1 to 84 months, mean = 48 and a cumulative follow-up in the aortic group (n = 385) equal to 1230 patients/year; the mitrals (n = 716) equal to 3018 patients/year. There were 102 late complications in 716 patients (14.24) and 51 in the aortic group (13.2). In relation to the age or the patients, 220 were under 20 years of age (mitrals = 176/aortics = 44) and in this subgroup the intrinsic valve failure was 43% of the mitral patients and 29% of the aortic group. The prosthetic endocardite was more frequent in the aortic group (45%) in compararison with the mitrals (29.7%). There were 62 reoperations in 1101 patients, with hospital mortality of 12.6%. The reoperations were more frequent in the mitral group, in patients below 20 years of age. Survival, considering only deaths related to the bioprosthesis, was 97.1% (32/1101). In the aortic group, 96.9% of patients were free of valve disfunction at the end of 7 years; among the mitrals, 95.2%. The major incidence of valve failure was encountered in the mitral patients, below 20 years of age; 85.3% were free of this complication at 7 years of follow-up. At the end of this study, the majority of the alive patients was functional classes I and II of the NYHA. Although the incidence of reoperation is significant, these findings are acceptable, specially because bioprosthesis offers a safer alternative than mechanical prosthesis. The present results suggest the continuation of research to obtain the ideal bioprosthesis, although current data is comparable to results abtained with similar bioprosthesis in the world literature.REFERÊNCIAS
1. ANTUNES, M. J. - Bioprosthetic valve replacement in children: long-term follow-up of 135 isolated mitral valve implantation. Eur. Heart J., 5(8): 913-915, 1984.
2. ANTUNES, M.J. - Thromboembolic complication and anticoagulants: compliant versus noncompliant patient populations. In: RABACO, G. & COOLEY, D. A. Heart valve replacement & future trends in cardiac surgery. Mount Kisco, NY, Futura Publishing Co. Inc., 1987. p. 307-317.
3. ANTUNES, M. J. & SANTOS, L. P. - Performance of glutaraldehyde preserved porcine bioprosthesis as a mitral valve substitute, in a young population group. Ann. Thorac. Surg., 37(5): 387-392, 1984. [MedLine]
4. BARBOSA, M. R. - Avaliação hemodinâmica da prótese heteróloga Biocor. Arq. Bras. Cardiol., 42(2): 123-128, 1984. [MedLine]
5. BLACK, M. M. - Accelerated fatigue testing of biological tissue heart valves. Proc. ESAO, 7(2): 315-319, 1980.
6. BOLOOKI, H.; MALLON, S.; KAISER, G. A. - Failure of Hancock xenograft valve: importance of valve position (4-to 9-year follow-up). Ann. Thorac. Surg., 36(3): 246-252, 1983. [MedLine]
7. BORTOLOTTI, U.; MILANO, A.; MAZZUCCO, A. - Results of reoperation for primary tissue failure of porcine bioprostheses. J. Thorac Cardiovasc Surg., 90(4): 564-600, 1982.
8. CARPENTER, A. - Current status and the future of tissue valves. In: DURAN, C. & ANGELL, W. W. Recent progress in mitral valve disease. England, Butterworth & Co. Ltd., 1984. p. 234-243.
9. COHN, L. H.; ALFRED, E. N.; DISESA, V. J. - Early and late risk of aortic valve replacement: a 12 year concomitant comparison of the porcine bioprosthetic and tilting disc prosthetic aortic valve. J. Thorac. Cardiovasc. Surg., 88(5, Parte 1): 695-705, 1984. [MedLine]
10. COHN, L. H.; MUDGE, G. H.; PRATTER, F. - Five to eight year folow-up of patients undergoing porcine heart valve replacement. N. Engl. J. Med., 304(2): 258-262, 1981.
11. CONTI, V. R.; NISHIMURA, A.; COUGHLIN, T. R.; FARRELL, R. W. - Indications for replacement of the Beall 103 and 104 disc valves. Ann. Thorac Surg., 42(3): 315-320, 1986. [MedLine]
12. CZER, L. S. & MATLOFF, J. M. - Experience with the St. Jude valve. In: RABAGO, G. & COOLEY, D. A. Heart valve replacement & future trends in cardiac surgery. Mount Kisco, NY, Futura Publishing Co. Inc. 1987. p. 153-166.
13. EMERY, R. W.; METTLER, E.; NICOLOFF, D. M. - A new cardiac prosthesis: the St. Jude Medical cardiac valve. In vivo results. Circulation, 60(Supl. 1): 48, 1979. [MedLine]
14. FENNERTY, M. B.; PICK, R. A.; CLARK, M. A. - Outlet strut fracture of a Björk-Shiley prosthesis in the mitral position. Am. J. Cardiol., 54(10): 923-931, 1984.
15. FERNANDEZ, J.; SAMUEL, A.; YANG, S. S. - Late thrombosis of the aortic Björk-Shiley prosthesis: its clinical recognition and management. Chest, 70(1): 12-16, 1976. [MedLine]
16. FUSTER, V.; PUMPHREY, C. W.; McGOON, M. D. - Systemic thromboembolism in mitral and aortic Starr-Edwards prostheses: 10-19-year follow-up. Circulation, 66(Supl. 1): I-157-I-161, 1982.
17. GALLO, I; NISTAL, F.; REVUELTA, J. M. - Incidence or primary tissue valve failure with Ionescu-Shiley pericardial valve. J. Thorac. Cardiovasc. Surg., 90(2): 278-280, 1985. [MedLine]
18. GALLO, I.; RUIZ, B.; NISTAL, F.; DURAN, C. M. G. - Degeneration in porcine bioprosthetic cardiac valves: incidence of primary tissue failure among 938 bioprostheses at risk. Am. J. Cardiol., 53(11): 1061-1066, 1984.
19. GALLUCCI, V.; VALFRE, C.; MAZZUCCO, A. - Heart valve replacement with the Hancock bioprosthesis: a 5-11 year follow-up. In: COHN, L. H. & GALLUCCI, V. Cardiac bioprostheses: Proceedings of the Second International Symposyum. New York, Yorke Medical Books, 1982. p. 9-24.
20. GEHA, A. S.; HAMMOND, G. L.; LAKS, H. - Factors affecting performance and thromboembolism after porcine xenograft cardiac valve replacement. J. Thorac. Cardiovasc. Surg., 83(4): 377-384, 1982.
21. GRAY, R.; CHAUX, A.; MATLOFF, J. - Early postoperative hemodynamic comparison of St. Jude cardiac prostheses and porcine xenografts, at rest and with stress. Circulation, 59, 60(Suppl. 2): 222, 1979. (Resumo).
22. HIRSCH, J.; DEYKIN, D.; POLLER, L. - "Therapeutic range" for oral anticoagulant therapy. Chest, 89(Supl.): 11S, 1986. [MedLine]
23. IMAMURA, E. & KITAMURA, M. - A trial of fixation modification for more physiological performance: preliminary hemodynamic evaluation open-fixation of bioprosthesis. In: GABAY, S. & CABROL, C. Calcification and degeneration of heart valve bioprosthesis. Paris, A. Ameur, 1988. p. 247-262.
24. JAMIESON, W. R. E.; GEREIN, A. N.; RICCI, D. R. - Carpentier-Edwards supra-annular porcine bioprosthesis: a new generation tissue valve (clinical and hemodynamic assessment). In: BODNAR, E. & YACOUB, M. Biologic and bioprosthetic valves: Proceedings of the Third International Symposium. New York, Yorke Medical Books, 1986. p. 141.
25. JAMIESON, W. R. E.; MUNRO, A. I.; MacNAB, J.; PATTERSON, M. W. H. - Porcine bioprostheses in patients 20 years and younger: is there a role for this prosthesis? In: BODNAR, E. & YACOUB, M. Biologic and bioprosthetic valves: Proceedings of the Third International Symposium. New York, Yorke Medical Books, 1986. p. 290.
26. KINSLEY, R. H.; COLSEN, P. R.; ANTUNES, M. J. - Medtronic-Hall valve replacement in a third-world population group. J. Thorac. Cardiovasc. Surg., 31(2): 69-74, 1983.
27. MAGILLIGAN, Jr., D. J. - Advantages and disadvantages of tissue valves. In: STAREK, P. J. K. Heart valve replacement and reconstruction. London, Year Book Medical Publishers Inc., 1987. p. 237-245.
28. MAGILLIGAN Jr., D. J.; HEINZERLING, R. H.; SMITH, D. - Fate of a second porcine bioprosthetic valve. J. Thorac. Cardiovasc. Surg., 85(3): 362-370, 1983. [MedLine]
29. MAGILLIGAN Jr., D. J. & TILLEY, B. - The porcine bioprosthetic valve: twelve years later. J. Thorac. Cardiovasc. Surg., 89(4): 499-507, 1985. [MedLine]
30. MARTINELL, J.; FRAILE, J.; ARTIZ, V. - Long-term comparative analysis of the Björk-Shiley and Hancock valves implanted in 1975. J. Thorac. Cardiovasc. Surg., 90(4): 741-749, 1985.
31. MILANO, A.; BORTOLOTTI, U.; TALENTI, E. - Calcific degeneration as the main cause of porcine bioprosthetic valve failure. Am. J. Cardiol., 53(8): 1066-1070, 1984. [MedLine]
32. MILLER, D. C. - Performance characteristics of the Starr-Edwards model 1260 aortic valve prosthesis beyound ten years: editorial rebuttal. J. Thorac. Cardiovasc. Surg., 88(2): 203-207, 1984.
33. MILLER, D. C. & OYER, P. E. - Ten-year clinical experience in 1651 patients with one type of tissue valve. In: STAREK, P. J. K. Heart valve replacement and reconstruction. London, Yeark Book Medical Publishers Inc., 1987. p. 175-189.
34. MILLER, D. C.; OYER, P. E.; MITCHELL, R. S. - Performance characteristics of the Starr-Edwards model 1260 aortic valve prosthesis beyond ten years. J. Thorac. Cardiovasc. Surg., 88(2): 193-207, 1984. [MedLine]
35. MITHA, A. S. - Clinical experience with the Lillenhei-Kaster cardiac prosthesis. J. Thorac. Cardiovasc. Surg., 72(3): 401-407, 1976. [MedLine]
36. MURPHY, D. A.; LEVINE, F. H.; BUCKLEY, M. J. - Mechanical valves: a comparative analysis of the Starr-Edwards and Björk-Shiley prostheses. J. Thorac. Cardiovasc. Surg., 86(5): 746-752, 1983. [MedLine]
37. ODELL, J. A. - Experience with tissue and mechanical valves in the pediatric age group. In: RABAGO, G. & COOLEY, D. A. Heart valve replacement & future trends in cardiac surgery. Mount Kisco, NY, Futura Publishing Co. Inc., 1987. p. 185-208.
38. OYER, P. E.; MILLER, D. C.; STINSON, E. B. - Clinical durability of the Hancock porcine bioprosthetic valve J. Thorac. Cardiovasc. Surg., 80(6): 824-833, 1980. [MedLine]
39. OYER, P. E.; STINSON, E. B.; MILLER, D. C. - Clinical analysis of the Hancock porcine bioprosthesis. In: COHN, L. H. & GALLUCCI, V. Cardiac bioprosthesis: Proceedings of the Second International Symposium. New York, Yorke Medical Books, 1982. p. 539-551.
40. OYER, P. E.; STINSON, E. B.; MILLER, D. C. - Thromboembolic risk and durability of the Hancock bioprosthetic cardiac valve. Eur. Heart J., 5(Supl. D): 81-85, 1984. [MedLine]
41. PASS, H. J.; CRAWFORD, F. A.; HOHN, A. R. - Cardiac valve replacement in children without anticoagulation. J. Thorac. Cardiovasc. Surg., 87(6): 832-835, 1984. [MedLine]
42. RABAGO, G. - Comparison of mechanical and biological prosthesis. In: RABAGO, G. & COOLEY, D. A. Heart valve replacement & future trends in cardiac surgery. Mount Kisco, NY, Futura Publishing Co. Inc., 1988. p. 245-256.
43. RABAGO, G. - A worldwide overview of valve usage. In: RABAGO, G. & COOLEY, D. A. Heart valve replacement & future trends in cardiac surgery. Mount Kisco, NY, Futura Publishing Co. Inc., 1987. p. 3-9.
44. SPENCER, F. C.; GROSSI, E. A.; CULLIFORD, A. T. - Experiences with 1643 porcine prosthetic valves in 1942 patients. Ann. Surg., 203: 691-700, 1986. [MedLine]
45. STEIN, P.; COLLINS, J.J.; KANTROWITZ, A. - Antithrombotic therapy in mechanical and biological heart valves and saphenous vein bypass grafts. Chests., 89(Supl.): 46S, 1986.
46. THUBRIKOR, M. J.; DECK, J. D.; AOUD, J. - Role of mechanical stress in calcification of aortic bioprosthetic valves. J. Thorac. Cardiovasc. Surg., 86(1): 115-125, 1983. [MedLine]
47. VRANDECIC, M. O. P. - Clinical experience with a new generation of porcine bioprosthesis. In: BODNAR, E. & YACOUB, M. Biologic bioprosthetic valves: Proceedings of the Third International Symposium. New York, Yorke Medical Books, 1986. p. 559-665.
48. VRANDECIC, M. O. P. - New bioprosthesis design. J. Cardiovasc. Surg., 28(Supl. 5): 18, 1987.